Kornimate/medical-research-clean huggingface dataset:
perioperative baroreflex sensitivity

Conditions: Hypertension; Hemodynamic Instability; Surgery

Summary: impaired baroreflex sensitivity (brs) is a marker of autonomous dysfunction, which may play an important role in the long-term development of hypertension. perioperative patients with hypertension is rapidly growing in all populations worldwide. however, no study has reported the values of brs in this cohort. the aim of this study was to estimate the value of brs for hypertension in a surgery cohort.

hypertension is known to be a major risk factor of end-organ damage, stroke and coronary mortality.it is estimated that one in six people worldwide, or nearly one billion, are affected by high blood pressure, and it is estimated that this number will increase to 1.5 billion by 2025. the world health organization also stated that high blood pressure is the most attributable cause of cardiovascular death.as the speed of aging is accelerated, the amount of perioperative hypertensive patients continue to increase. perioperative hypertension had been shown to be a risk factor for the development of perioperative morbidity and mortality.although it has aroused people's attention, there still lack of system evaluation and effective control. therefore, it's urgent and necessary to assess and intervene perioperative situation of hypertensive patients. the pathogenesis of hypertension is very complex, while the exact mechanism is still unclear. the dysfunction of autonomic activity, marked in particular by sympathetic overactivity and reduced parasympathetic activity, has been hypothesized to underlie the development of hypertension.baroreflex control is one of the key mechanisms responsible for the short-term control of blood pressure.it acts as a closed loop, negative feedback mechanism, aimed at stabilizing blood pressure around a set point value.the impairment of baroreflex sensitivity (brs) is know as the predictive factor of mortality in hypertension. a large of clinical and basic research indicated the existence of autonomic dysfunction and impaired brs in patients with essential hypertension. however, no study has reported the values of perioperative brs, especially in hypertensive patients . therefore, the aim of this study was to estimate the value of brs for hypertension in a surgery cohort, and to explore the functional status of autonomic nervous system, may provide reference for clinical treatment.

Eligibility criteria:
inclusion criteria: 1. patients undergoing ordinary thoracic surgery and age between 18 and 70; 2. american society of anesthesiologists(asa) classification i to ii level; 3. willing to participate in this study and signed an informed consent exclusion criteria: 1.patients with diabetes mellitus, cardiopulmonary dysfunction, severe liver and kidney dysfunction and disease of nervous system;

Keywords: hypertension perioperative baroreflex sensitivity
surgical evacuation of abortion under ultrasonographic guide

Conditions: Abortion

Summary: abortion is considered the most common cause of fetal demise all over the world. the majority of cases occur in the first trimester. the termination of abortion may be by medical or surgical methods, however; the surgical methods represent the greater part of termination. therefore, the safety of this procedure is a worldwide public health concern. many clinical studies have reported the safety of surgical evacuation in the first trimester. the suction-aspiration or vacuum aspiration is the most common surgical method of induced abortion. this consists of removing the fetus, embryo, placenta, and membranes by suction using a manual syringe or electric pump. however; these techniques always need cervical dilation before aspiration. the menstrual extraction does not require cervical dilation and can be used in very early pregnancy.


Eligibility criteria:
inclusion criteria: * women with non-viable first trimester intrauterine pregnancy * no contraindication to surgical evacuation under general anesthesia exclusion criteria: * gestational age more than 13 weeks * hemodynamically unstable * suspicion of an ectopic pregnancy
chronic pain and opioid dependence assessment and treatment

Conditions: Chronic Pain; Opioid Dependency

Summary: this study involves the development of an integrated psychotherapy that addresses both chronic pain and opioid dependence(pod).

to conduct a pre-pilot study with 20 pod patients to a) evaluate the acceptability and potential efficacy of specific sessions (i.e., reduced illicit opioid use as assessed by urine toxicology and self-report findings, and decreased pain as evidenced by attenuated pain intensity and pain interference on self-report measures from baseline throughout treatment) for inclusion in integrated cognitive behavioral therapy (cbt) for pod and the sequence of sessions, b) assess patients' satisfaction with integrated cbt as evidenced by qualitative feedback from individual exit interviews, and c) develop and modify initial therapist training and process rating measures. products will include a) a manual for integrated cbt for pod to be used in opioid treatment programs and primary care settings with pod patients, b) therapist training materials, and c) process rating instruments.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * currently in methadone maintenance treatment (mmt) at the apt foundation in new haven, ct * opioid dependence * experience moderate to severe chronic pain exclusion criteria: * current suicide or homicide risk * are unable to complete the informed consent or surveys because of psychiatric impairment * have cognitive impairment * are unable to read or understand english

Keywords: chronic pain opioid dependence cognitive behavioral therapy (cbt)
desflurane and postoperative sleep quality in patients undergoing elective breast surgery

Conditions: Desflurane; Propofol; Postoperative Sleep; PSQI; Breast Tumor

Summary: this study intends to investigate the effects of desflurane on postoperative sleep quality to guide perioperative patient management.


Eligibility criteria:
inclusion criteria: 1. undergoing elective breast surgery 2. age 18-75 years old 3. asa-ps grade i or ii 4. those who voluntarily participate in the research and sign the informed consent exclusion criteria: 1. cognitive impairment (mmse \<27) before the operation 2. the patients received adjuvant chemotherapy before the operation 3. at present, they are taking psychoactive, opioid, anti-anxiety, and hypnotic drugs 4. known or treated patients with obstructive sleep apnea 5. patients with other cancers
yf476 and type ii gastric carcinoids

Conditions: Zollinger-Ellison Syndrome

Summary: this study will evaluate whether treatment with yf476 is safe and effective in reducing the size of type ii gastric carcinoid tumours, or limiting the abnormal growth of gastric ecl cells, in patients with zollinger-ellison syndrome.


Eligibility criteria:
inclusion criteria: 1. men; post-menopausal women; pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy; or pre-menopausal women using one of the allowed methods of contraception: condom and spermicide or intra-uterine device. 2. patients with serum gastrin \>250 pg/ml. 3. hepatic function: ast and alt ≤2.0 x uln; total bilirubin ≤1.0 x uln. 4. renal function: serum creatinine \<1.0 x uln. 5. haematologic function: hb ≥10.0 g/dl; wbc ≥3.5 x 10e9 /l; anc ≥1.5 x 10e9 /l; platelets ≥100 x 10e9 /l. 6. coagulation parameters: inr or pt ≤1.0 x uln; ptt ≤1.0 x uln. 7. ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial. 8. willingness to give fully-informed, written consent. exclusion criteria: 1. patients under 18 years. 2. women who are pregnant, lactating or using a steroid contraceptive. 3. prior gastric resection or bypass. 4. planned gastrinoma resection during the study period. 5. patients on somatostatin analogues, except for those on therapy for \>6 months with stable or worsening carcinoids. 6. inability to tolerate endoscopy, or refusal of endoscopy. 7. physical findings, ecg (especially prolonged qtc interval \>450 msec), or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject. 8. certain medicines and herbal remedies taken during the 7 days before visit 2. 9. participation in a trial of an imp within the previous 28 days. 10. presence of drug or alcohol abuse. 11. history or baseline findings of: * type 1 diabetes mellitus; * pancreatitis (baseline amylase and/or \>2.0 x uln); * hepatitis b, hepatitis c or hiv; * malabsorption syndrome or inability to swallow or retain oral medicine; * major surgery \<28 days prior to enrolment; * ecog performance status \>2; or * another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in-situ. * also, any clinically significant and uncontrolled major morbidity including but not limited to; serious cardiac disease (unstable angina, s/p myocardial infarction \<1 month); respiratory disease (advanced copd or pulmonary fibrosis); uncontrolled hypertension; or active systemic infection.

Keywords: yf476 netazepide gastric carcinoids zollinger-ellison syndrome
the mediterranean full-fat dairy study

Conditions: Cardiovascular Disease; Dyslipidemia; Inflammation

Summary: a mediterranean dietary pattern emphasizing an abundance of plant-based foods including nuts, moderate intakes of fish, poultry and low-fat dairy products, and use of extra virgin olive oil as the main source of fat has been associated with reduced risk of cardiovascular disease (cvd), and such a pattern has been advocated by the 2015 u.s. dietary guidelines advisory committee. the strongest experimental support for this recommendation derives from the success of the recent predimed cvd outcomes trial, and studies indicating that a mediterranean-style diet improves lipoprotein and oxidative markers of cardiovascular disease risk in comparison to either low-fat or western dietary patterns. however, in none of these studies were comparisons made between the effects of mediterranean-style diets with low-/nonfat vs. full-fat dairy foods. the overall objective of the present proposal is to determine whether the inclusion of full-fat rather than low- and nonfat dairy foods in a mediterranean dietary pattern based on that used in the predimed study results in similar improvements in biomarkers of cvd risk. specifically, we will test the hypotheses that 1) a standard mediterranean diet will lower ldl-c and apob compared to a western diet; 2) modification of the mediterranean diet by replacing low-fat dairy products with high-fat dairy (3 servings/day; high-dairy fat mediterranean diet) will not significantly increase ldl-c and apob but may raise large buoyant ldl particles compared with a standard mediterranean diet; and 3) the high dairy fat and standard mediterranean diets will result in comparable reductions in levels of inflammatory markers and oxidized ldl, and improvements in endothelial function compared to a western diet.


Eligibility criteria:
inclusion criteria: * bmi 25-35 kg/m2 * weight stable for \> 3 months * agrees to abstain from alcohol or dietary supplements during the study exclusion criteria: * history of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, hiv, or cancer (other than skin cancer) in the last 5 years. * current use of hormones or drugs knowns to affect lipid metabolism * use of nicotine products or recreational drugs * abnormal tsh * pregnant or breastfeeding * total- and ldl- cholesterol \> 95th percentile for sex and age * fasting triglyceride \> 500 mg/dl * fasting blood sugar \> 126 mg/dl * blood pressure \>160/95 mm hg * allergy to or unwillingness to consume study foods

Keywords: diet mediterranean cholesterol inflammation
a step for patients prior to undergoing tavr: a pilot study

Conditions: Frail Elderly; Aortic Valve Stenosis

Summary: the aim of this pilot study is to establish whether a supervised tavr exercise program (step) can safely improve the frailty status in patients with symptomatic severe aortic valve stenosis prior to undergoing transcatheter aortic valve replacement (tavr).

tavr is an approved alternative therapy for patients with severe aortic valve stenosis who are deemed inoperable or high-risk for surgical aortic valve replacement (savr). despite a very high procedural success rate (\>95%), mortality rates after tavr at 1- and 2-year follow-up remain ≥25% and ≥34%, respectively. it is becoming increasingly evident that frailty, as a clinical syndrome, has a large impact on this long term mortality. in a study by green, et al. frailty status was independently associated with increased 1-year mortality (or=3.5) after tavr. the investigators' own retrospective analysis showed that impaired mobility and malnutrition were significantly associated with a longer hospital length of stay (5 days vs. 3 days), and increased total cost (on average, an additional $10,000 per patient). given the phenotype of frailty is characterized by reductions in muscle mass, strength, endurance and activity level, a step is ideally suited to counteract these impairments. this pilot study aims to establish whether a step can safely improve the frailty score in patients with symptomatic severe aortic valve stenosis prior to undergoing tavr. this single-center pilot study will be conducted in partnership between heart care midwest (hcmw), osf st. francis medical center (osf sfmc), and university of illinois college of medicine at peoria (uicomp). uicomp center of outcomes research will provide analytical support. the study will be funded by an operational research grant from osf sfmc.

Eligibility criteria:
inclusion criteria: * all adult patients scheduled to undergo first-time elective tavr exclusion criteria: * vulnerable populations including prisoners, pregnant females and patients less than 18 years age. * patients with history of unstable angina, myocardial infarction, or decompensated heart failure in the week prior to screening * patients with physical limitations (i.e. debilitating stroke, amputation, unable to complete initial screening frailty profile) * patients with advanced dementia or cognitive deficits (i.e. unable to follow instructions of initial screening frailty profile) * exercise-induced arrhythmias

Keywords: transcatheter aortic valve disease supervised tavr exercise program
effect of risedronate on bone morbidity in fibrous dysplasia of bone

Conditions: Fibrous Dysplasia of Bone

Summary: this trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.

in open pilot studies, it has been suggested that bisphosphonates may alleviate bone pain and help decrease the surface of osteolytic lesion in patients with fibrous dysplasia of bone (fd). so, in this randomized placebo controlled trial, we test the hypothesis that the bisphosphonate risedronate reduces bone pain in patients with fd (study i, one year duration) and decrease osteolytic lesions (study ii, three years duration). patients will take risedronate during 2 months courses, every 6 months or a matching placebo. dosage will be : 30mg tablet/day for adults and 5mg tablet x 2,4 according to the age and weight of the child. all participants will receive calcium and vitamin d. all patients with renal phosphate wasting will receive an oral phosphate supplement.

Eligibility criteria:
inclusion criteria: * study i: patients with fd, with bone pain intensity above 3 on visual analogical scale from 0 to 10 * study ii: patients with fd with at least one osteolytic lesion and no current bone pain exclusion criteria: * patients \< 8 years old * other diseases affecting bone metabolism * patients with malignant diseases or other conditions likely to reduce their life expectancy to less than 3 years * patients with history of significant upper gastrointestinal disorders * renal failure (creatinine clearance \< 25 ml/mn) * severe liver disease * history of iritis or uveitis * rickets or osteomalacia * allergy to bisphosphonates * pregnancy or lactation * prior treatment with a bisphosphonate * laboratory abnormalities that may be considered as clinically significant by trial physicians

Keywords: fibrous dysplasia of bone mac cune albright syndrome bisphosphonates risedronate
super power in bai

Conditions: Conductive and Sensorineural Hearing Loss

Summary: the purpose of this study is to assess the benefit of new super-power bone-anchored hearing aid (baha) processors in baha users. bahas are able to help people with mixed/conductive and single-sided hearing loss when they are unable to use or receive limited benefit from traditional hearing. until recently, bahas were only recommended to people with up to a moderate hearing loss. new super-power baha processors may be able to help people who previously were not candidates for bahas or received limited benefit from them. the information collected in this study may lead to improved evaluation of and expanded treatment options for people considering baha. different types of hearing tests will be used to compare the devices.

the objective of this study is to assess the benefit of new super-power bone-anchored hearing aid (baha) processors in baha users. bahas are able to help people with mixed/conductive and single-sided hearing loss when they were not receiving benefit from traditional hearing aids or could not use them due to differences in their ears related to surgery or congenital anomalies. stronger super-power processors may be able to help individuals who previously did not meet candidacy for baha. this study will evaluate how much benefit they are getting from their current devices compared to new super-power devices. the information collected in this study may lead to improved evaluation of patients considering baha implantation and expanded treatment options for new and existing baha users. primary outcome measures will include hearing threshold and speech perception measures. all devices are commercially available and fda approved.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * meet candidacy criteria for a high gain super-power processor with a fitting range up to 65 db * native english speaker exclusion criteria: * do not meet inclusion criteria
efficacy and safety of apitegromab for the treatment of adults who are overweight or obese

Conditions: Overweight and Obesity

Summary: a phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to glp-1 agonist therapy in subjects with overweight or obesity

this phase 2 randomized, double-blind, placebo-controlled, multicenter study will assess the safety, efficacy, and pharmacokinetics (pk) of apitegromab when used as an adjunctive therapy to glp-1 agonist therapy in subjects with overweight and obesity and without diabetes. each subject will receive either semaglutide or tirzepatide, depending upon availability, and will maintain that course throughout the treatment period. in addition, all subjects will be randomized 1:1 to receive either apitegromab or placebo during the treatment period.

Eligibility criteria:
inclusion criteria * able to comprehend the informed consent process and provide written informed consent prior to study enrollment and the conduct of any study-related assessments to study enrollment and the conduct of any study-related assessments * male or female, age ≥ 18 and ≤ 65 years at the time of informed consent * stable body weight (±5 kg) within 90 days of screening * at screening, a bmi of: 1. ≥30.0 kg/m2 to ≤45.0 kg/m2 or 2. ≥27.0 kg/m2 to \<30.0 kg/m2 with the presence of 1 or more weight-related comorbid condition(s). note: see exclusion criteria for specific organ class disease parameters exclusion criteria: * history of or active cardiovascular, neurovascular, peripheral vascular, pulmonary, hepatic, pancreatic, neuromuscular, and/or psychiatric disease * active malignancy, other than local subcutaneous squamous cell and basal cell carcinomas * history of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to screening * history of type 1 diabetes or active type 2 diabetes (t2d). if there was a history of t2d and it resolved, then the resolution must have occurred \>12 months prior to screening. prediabetes managed with nonpharmacologic approaches (exercise and diet) is not an exclusion

Keywords: overweight obesity
bismuth-containing quadruple therapy for helicobacter pylori first-line treatment of different tetracycline doses

Conditions: Helicobacter Pylori Infection

Summary: the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. the subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13c-urea breath test. calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. if the subject meets the selection criteria but not the exclusion criteria, and signs an informed consent form, the researchers randomized the subjects in groups: subjects received a dose and frequency of tetracycline 500mg tid or qid of bismuth-containing quadruple eradication therapy. the medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects will review the 13c-urea breath test, and the researcher records the results. after all subjects were tested, the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group were calculated. according to the course of treatment, it is randomized into a tid treatment group and a qid treatment group. the two groups of bismuth quadruple regimens are the same, as follows: tid group: amoxicillin 1000mg bid+ tetracycline 500mg tid+ bismuth + esomeprazole 20mg bid qid group: amoxicillin 1000mg bid+ tetracycline 500mg qid+ bismuth + esomeprazole 20mg bid

Eligibility criteria:
inclusion criteria: * patients aged 18-70. * patients with h.pylori infection (positive for rapid urease test or 13c/14c-urea breath test). * patients who have never received h. pylori eradication treatment. exclusion criteria: * patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%. * patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial. * patients with active gastrointestinal bleeding. * patients with a history of upper gastrointestinal surgery. * patients allergic to treatment drugs. * patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks * patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse * patients who are unwilling or incapable to provide informed consents.

Keywords: helicobacter pylori tetracycline bismuth-containing quadruple regimen